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Abstract
Purpose: Carbon monoxide (CO) is an accepted cytoprotective molecule. The extent and mechanisms of protection in
neuronal systems have not been well studied. We hypothesized that delivery of CO via a novel releasing molecule (CORM)
would impart neuroprotection in vivo against ischemia-reperfusion injury (IRI)-induced apoptosis of retinal ganglion cells
(RGC) and in vitro of neuronal SH-SY5Y-cells via activation of soluble guanylate-cyclase (sGC).
Methods: To mimic ischemic respiratory arrest, SH-SY5Y-cells were incubated with rotenone (100 nmol/L, 4 h) 6 CORM
ALF186 (10–100 mmol/L) or inactivated ALF186 lacking the potential of releasing CO. Apoptosis and reactive oxygen species
(ROS) production were analyzed using flow-cytometry (Annexin V, mitochondrial membrane potential, CM-H2DCFDA) and
Western blot (Caspase-3). The impact of ALF1866 respiratory arrest on cell signaling was assessed by measuring expression
of nitric oxide synthase (NOS) and soluble guanylate-cyclase (sGC) and by analyzing cellular cGMP levels. The effect of
ALF186 (10 mg/kg iv) on retinal IRI in Sprague-Dawley rats was assessed by measuring densities of fluorogold-labeled RGC
after IRI and by analysis of apoptosis-related genes in retinal tissue.
Results: ALF186 but not inactivated ALF186 inhibited rotenone-induced apoptosis (Annexin V positive cells: 2562%
rotenone vs. 1461% ALF186+rotenone, p,0.001; relative mitochondrial membrane potential: 1764% rotenone vs. 5563%
ALF186+rotenone, p,0.05). ALF186 increased cellular cGMP levels (3365 nmol/L vs. 2363 nmol/L; p,0.05) and sGC
expression. sGC-inhibition attenuated ALF186-mediated protection (relative mitochondrial membrane potential: 5563%
ALF186+rotenone vs. 2061% ODQ+ALF186+rotenone, p,0.05). ALF186 protected RGC in vivo (IRI 12556327 RGC/mm
2 vs.
ALF186+IRI 2036683; p,0.05) while sGC inhibition abolished the protective effects of ALF186 (ALF186+IRI 2036683 RGC/
mm
2 vs. NS-2028+ALF186+IRI 12636170, p,0.05).
Conclusions: The CORM ALF186 inhibits IRI-induced neuronal cell death via activation of sGC and may be a useful treatment
option for acute ischemic insults to the retina and the brain.
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Introduction
Ischemic injury to neuronal cells might occur in the periopera-
tive period during major cardiovascular but also non-cardiac
surgical procedures [1]. Against current dogma that carbon
monoxide (CO) is poisonous, particularly to the brain, emerging
data suggest that at low doses CO provides potent neuroprotection
by its anti-inflammatory and anti-apoptotic properties [2,3]. The
application of CO releasing molecules (CORMs) may be a valuable
alternative to inhaled CO, because they can be administered to
biological systems via systemic routes and potentially in a tissue-
specific manner thus avoiding unreliable inhaled application and
allowing safe administration to target organs such as the central
nervous system. CORMs suppress the inflammatory response in
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However, other findings have elicited some confusion as to the
consistency of the neuroprotective effects, which may reflect the
choice of CORM. The well-described ruthenium based, water-
soluble CORM-3 is effective when given before or late after
neuronal injury but not when given early afterwards [5]. Here, we
present data that a molybdenum-based, water-soluble CORM
(ALF186) possesses a different CO release profile releasing CO in
a dose- and oxygen-dependent manner after administration [6].
ALF186 has shown protective effects in vivo in models of acute
inflammation [7,8] and in the regulation of vasomotor tone [9].
Given the anti-inflammatory and vascular effects of CO and
ALF186 we hypothesized that ALF186 would be an ideal modality
to assess the potential neuroprotective properties of ALF186 in vitro
and in vivo in models of ischemic injury. The mechanisms of
CORM-mediated protective effects have not been well studied in
neuronal systems. This is of particular importance considering the
large amount of data that CO may be neurotoxic. Heme-
containing proteins are well-described cellular targets given the
affinity of CO for ferrous iron in heme. Binding of CO to heme
can alter enzymatic function both positively or negatively and
include soluble guanylate-cyclase (sGC), nitric oxide synthase
(NOS) and NADPH oxidase as well as the mitochondrial
cytochrome c oxidase complexes [10]. The role of these ‘‘primary
targets’’ in mediating anti-inflammatory [11], anti-proliferative
[12] and vasoactive [13] effects of CORMs have been character-
ized in non-neuronal systems, but not in neuronal systems.
Indirect effects of CO on non-heme proteins have also been shown
to contribute to its protective effects [10].
CO has emerged as a gaseous neurotransmitter that modulates
neuronal cGMP levels [14]. CO and CORMs are known sGC-
activators, leading to a moderate increase in cGMP production
[9,13,15]. Growing evidence supports a role for the sGC-cGMP
pathway in CO-mediated protection of neuronal cells against
apoptosis [2,16]. However, little is known whether CORM-
mediated neuroprotective effects occur through this pathway.
Protective effects that occur through activation of sGC-cGMP
signal transduction seem to be mediated through protein kinase
G1 (PKG1) activation [16] albeit the distinct cellular downstream
targets for these protective effects remain unknown.
Materials and Methods
Reagents
The carbon monoxide releasing molecule ALF186 ([Mo(CO)3(-
histidinato)]Na; Fig. 1; Alfama Inc., Lisbon, Portugal) was kindly
provided by C. Roma ˜o [6,8]. It was freshly dissolved in PBS prior
to cell culture treatment. The inactive compound iALF186 was
prepared by dissolving ALF186 in PBS and incubated for 24 h
under exposure to air and light. After 24 h, the solution was
bubbled with nitrogen to remove residual carbon monoxide.
Rotenone was purchased from Sigma Aldrich (Taufkirchen,
Germany). It was freshly prepared by dissolving in dimethylsulf-
oxide (DMSO) prior to the experiments. DMSO concentration in
cell culture media did not exceed 0.5%.
The inhibitors of proteinkinase G-1(PKG1; KT5832), the
inhibitor (ODQ) and the inductor (YC-1) of the soluble
guanylate-cyclase (sGC) and the cGMP-analogue 8-Br-cGMP
were obtained from Sigma Aldrich, as were the inhibitors of the
nitric oxide synthase (NOS) L-NAME and of the NADPH oxidase
DPI (diphenylene iodonium).
Cell Culture and Treatment
Neuroblastoma cells (cell line SH-SY5Y; ATCC No. CRL-
2266) were cultured in DMEM medium (with penicillin/strepto-
mycin, 1% glutamate and 10% fetal bovine serum) in a humidified
atmosphere with 5% carbon dioxide at 37uC constant temperature
until 80% confluence was achieved. The cells were usually seeded
in 6 well culture plates at a density of approximately 3610
5 per
well 24 h prior to individual treatment. Before rotenone
treatment, the cells were transferred into media containing 0.5%
fetal bovine serum, to prevent inactivation of rotenone by protein
binding. Cells were pre-treated with 10–100 mmol/L ALF186 or
iALF186 30 min before induction of apoptosis with 100 nM
Rotenone. After 4 h of rotenone-treatment, cells were collected for
quantification of apoptosis or protein and gene expression analysis.
For assays analyzing the influence of ALF186 alone without
rotenone-treatment, cells were collected 1 h after ALF186
treatment.
Quantification of Apoptosis
Staining with Annexin V-FITC and propidiumiodide (Becton
Dickinson, Heidelberg, Germany) and flow-cytometric analyses
were done as previously described [17]. Western Blots were done
as previously described [17] using antibodies against cleaved
Caspase-3 (#9664 from Cell Signaling Technology, Danvers, MA,
USA) and GAPDH (#CSA-335 from Enzo Lifesciences, Ply-
mouth, PA, USA).
Quantification of Mitochondrial Membrane Potential Loss
Mitochondrial membrane potential (DYm) was quantified using
the Mito-Probe JC-1 Assay (Molecular Probes, Invitrogen,
Darmstadt, Germany). SH-SY5Y cells were stained with
2 mmol/L JC-1 for 15 min prior to cell collection after treatment
with rotenone, ALF186 or inhibitors as indicated in the individual
experiments. Cells were analyzed using flow-cytometry. JC-1
exhibits mitochondrial membrane potential-dependent accumula-
tion in mitochondria, which leads to formation of aggregates and
a fluorescence emission shift from green to red. As a consequence,
mitochondrial depolarization is indicated by a decrease in the ratio
of red/green fluorescence intensity. The ratio between red and
green fluorescence intensity was calculated. While the ratio in
untreated cells was set to 100%, the difference compared to
treated cells was used to describe a loss in mitochondrial
membrane potential.
Analysis of Primary Carbon Monoxide Targets
Soluble guanylate cyclase (sGC) and corresponding cGMP were
analyzed using a cGMP detection kit (Cell Signaling Technology,
Danvers, MA, USA). Expression of the sGC a and b1 subunits
were quantified using RT-PCR, while the subunit proteins were
visualized with Western blot analyses (sGC a1: #160895; sGC b1:
#160897 from Cayman Chemical, Ann Arbor, MI, USA).
Selective induction of sGC was achieved using YC-1 and selective
Figure 1. Chemical structure of ALF186. Carbon monoxide
liberating compound containing a central molybdenum atom.
doi:10.1371/journal.pone.0060672.g001
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for 30 min respectively. Also, a cell permeable cGMP-analogue (8-
Br-cGMP, 1 mmol/L, 30 min) was used to mimic sGC activation.
Protein kinase G-1 (PKG1, cGK1) as a downstream target of
cGMP was inhibited with the selective inhibitor KT5823 (1 mmol/
L, 1 h). Expression of the inducible (i) and neuronal (n) isoforms of
nitric oxide synthase (NOS) was analyzed using Western blot
(iNOS: #2977; nNOS: #4236 from Cell Signaling Technology,
Danvers, MA, USA). Inhibition of NOS was achieved by
incubation with L-NAME (50 mmol/L, 30 min) and inhibition
of NADPH oxidase was performed using diphenylene iodonium
(DPI, 10 mmol/L, 1 h).
Quantification of Nitric Oxide Production
Nitric oxide production was quantified by measurement of total
nitrite concentration in cell supernatants using the Griess Method
(Nitric Oxide Colorimetric Assay Kit, BioVision, Milpitas, CA,
USA) following the manufacturer’s instructions. Absorbance at
540 nm was then read on a microplate reader (Molecular Devices,
SpectraMax, Biberach, Germany) to quantify total nitrite content
in the samples.
Reactive Oxygen Species
Quantification of reactive oxygen species (ROS) was assessed
using the fluorescence dye CM-H2DCFDA (Invitrogen, Karlsbad,
Germany) by flow-cytometry. Incorporation of CM-H2DCFDA is
indicative of intracellular formation of ROS and can be assessed
by quantification of fluorescence intensity in FL-1. A positive
control was obtained using phorbol-myristate-acetate (PMA,
Sigma Aldrich, Taufkirchen, Germany) at a concentration of
1 mmol/L for 5 min.
Animals
Adult male and female Sprague-Dawley rats (1:1, 280–350 g
body weight, Charles River, Sulzfeld, Germany) were used.
Animals were fed a standard rodent diet ad libitum while kept on
a 12-h light/12-h dark cycle. All procedures involving animals
concurred with the approval of The Association for Research in
Vision and Ophthalmology and were approved by the Committee
of Animal Care of the University of Freiburg (Permit Number: 35-
9185.81/G-11/81). All types of surgery and manipulations were
performed under general anesthesia with isoflurane/O2 for
retrograde labeling with fluorogold or a mixture of intraperitone-
ally administered ketamine 50 mg/kg (Ceva-Sanofi, Germany)
and xylazine 2 mg/kg (Ceva-Sanofi) for the ischemia reperfusion
experiments. Body temperature was maintained at 3760.5uC with
a heating pad controlled by a rectal thermometer probe. After
surgery, buprenorphine (50 mg/kg; Essex Pharma, Germany) was
applied subcutaneously to treat pain. While recovering from
anesthesia, animals were placed in separate cages and gentamicin
ointment (RefobacinH; Merck, Darmstadt, Germany) was applied
on ocular surfaces and skin wounds. The number of animals used
for RGC quantification and molecular analysis was n=6 per
group.
Retrograde Labeling of RGC
Rats were anesthetized with isoflurane, placed in a stereotactic
apparatus (Stoelting, Kiel, Germany) and retrograde RGC-
labeling was done as described previously [18]: The skin overlying
the skull was cut open und retracted. The lambda and bregma
sutures served as landmarks for drilling 3 holes on each site of the
bregma suture. A total amount of 7.8 ml fluorogold (FG)
(Fluorochrome, Denver, CO, USA) dissolved in 10% dimethylsulf-
oxide in PBS was injected into both lateral superior colliculi
through the drilling holes. To ensure adequate retrograde
transport of FG into the RGC’s perikarya, further experimental
interventions were done 7 days after retrograde labeling.
Retinal Ischemia/Reperfusion Injury and Treatment with
ALF186
Rats were anesthetized intraperitoneally with xylazine and
ketamine. To evaluate a neuroprotective effect of carbon
monoxide released from ALF186, animals were randomized to
receive treatment with ALF186 (10 mg/kg body weight i.v.,
dissolved in PBS) or PBS (vehicle controls) alone 30 min prior to
initiation of ischemia. A third group received NS-2028 (inhibitor
of sGC; Sigma Aldrich; 7 mg/kg body weight i.v. dissolved in
DMSO/PBS) 30 min before ALF186 treatment and subsequent
ischemia/reperfusion injury. Retinal ischemia/reperfusion injury
was performed as described previously [3]. Briefly the anterior
chamber of the left eye was cannulated with a 30-gauge needle
connected to a reservoir containing 0.9% NaCl. Intraocular
pressure was increased to 120 mm Hg for 60 min and ocular
ischemia was confirmed microscopically by interruption of the
ocular circulation. Rats without immediate recovery of retinal
perfusion at the end of the ischemic period or those with lens
injuries were excluded from the investigation, since the latter
prevents RGC death and promotes axonal regeneration.
RGC Quantification
Animals were killed by CO2-inhalation 7 days after ischemia.
Retinal tissue was immediately harvested, placed in ice-cold Hanks
balanced salt solution and further processed for whole mount
preparation. Retinae were carefully placed on a nitrocellulose
membrane with the ganglion cell layer (GCL) on top. After
removing the vitreous body, retinae were fixed in 4% para-
formaldehyde for 1 h and then embedded in mounting media
(Vectashield; Axxora, Loerrach, Germany). The densities of FG-
positive RGC were determined using a fluorescence microscope
(AxioImager; Carl Zeiss, Jena, Germany) and the appropriate
bandpass emission filter (FG: excitation/emission, 331/418 nm),
as previously described [19]. Briefly, we photographed 3 standard
rectangular areas (0.200 mm60.200 mm=0.04 mm
2) at 1, 2 and
3 mm distal from the optic disc in the central regions of each
retinal quadrant. Hence, we evaluated an area of 0.48 mm
2 per
retina (1260.04 mm
2). Assuming an average retinal area of about
50 mm
2 in rats [20], we evaluated about 1% of the retina. To
calculate the average RGC density in cells/mm
2, we multiplied
the number of analyzed cells/0.04 mm
2 by 25. Secondary
fluorogold stained activated microglia cells (AMC) after RGC
phagocytosis were identified by morphologic criteria and excluded
from calculation. All averaged data are presented as mean RGC
densities [cells/mm
2] 6 SD.
Real Time Polymerase Chain Reaction (RT-PCR)
For the in vivo experiments, retinal tissue was harvested 12 h
after IRI. For the in vitro experiments with SH-SY5Y neuroblas-
toma cells, cells were lysed 1 h after ALF186 or 4 h after rotenone
treatment. Total RNA from each retina or from 0.5610
6 SH-
SY5Y cells was extracted using a column-purification based kit
(RNeasy Micro KitH, Qiagen, Hilden, Germany) according to
manufacturer’s instructions. Reverse transcription was performed
with 25 to 250 ng of total RNA using random primers (High
Capacity cDNA Reverse Transcription Kit, Applied Biosystems,
Darmstadt, Germany). RT-PCR was done with a TaqManH
probe-based detection kit (Applied Biosystems), using the following
CO Abrogates Ischemic Insult to Neuronal Cells
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1. sGC a1 human/Hs01015570_m1; 2. sGC b1 human/
Hs00168336_m1; 3. GAPDH human/4326317E; 4. Bax rat/
Rn02532082_g1; 5. Bcl-2 rat/Rn99999125_m1; 6. Caspase-3 rat/
Rn00563902_m1; 7. sGC a1 rat/Rn00567252_m1; 8. sGC b1
rat/Rn00562775_m1; 9. GAPDH rat/4352338E.
PCR assays were then performed on a RT-PCR System (ABI
Prism 7000, Applied Biosystems) with the following cycling
conditions: 95uC for 10 min, 40 cycles of 95uC for 10 sec and
60uC for 1 min. Reaction specificity was confirmed by running
appropriate negative controls. Cycle threshold (CT) values for
each gene of interest were normalized to the corresponding CT
values for GAPDH (DCT). Relative gene expression in IR-injured
retinal tissue was calculated in relation to the corresponding gene
expression in the non-injured retinal tissue of each individual
animal (DDCT). For in vitro experiments, relative gene expression
in cells treated with ALF186 and rotenone was calculated in
relation to gene expression in untreated cells (DDCT).
Statistical Analyses
All data with normal distribution are presented as means 6 SD.
Data without normal distribution are presented as median 625
th/
75
th percentile. For in vitro studies, one-way ANOVA was used for
between-group comparisons with post hoc Holm Sidak test and
Kruskal Wallis one-way ANOVA on ranks with post hoc SNK-test
for data with lack of normal distribution. For the in vivo studies, we
wished to detect a 50% difference in RGC densities by
intervention with ALF186. Based on previously published data
[3] and assuming an expected SD of 10%, an a priori power
analysis (a=0.05 with two-sided hypothesis, power 80%) indicated
that a sample size of six animals per group would be sufficient to
detect such a difference. Two-way ANOVA (RGC densities:
Factor A=ischemia with two levels: 1. control and 2. IRI; factor
B=intervention with three levels: 1. vehicle, 2. ALF186, 3. NS-
2028+ALF186) was used for between-group comparisons with post
hoc Holm-Sidak test. Data were analyzed with a computerized
statistical program (SigmaStat for Windows Version 3.1, Systat
Software Inc., San Jose, CA, USA). P,0.05 was considered
statistically significant.
Results
ALF186 Attenuates Rotenone-induced Apoptosis
The ability of CO to prevent apoptosis of non-neuronal cells has
been well described and thus led us to investigate the
neuroprotective properties of ALF186 on cell death. We induced
apoptosis with the mitochondrial poison rotenone in SH-SY5Y
neuroblastoma cells in order to mimic the changes in cellular
respiration in vitro as occurs during IRI in vivo. Exposure of cells to
rotenone significantly increased the percentage of Annexin V
positive cells (Fig. 2A–2B). ALF186, but not inactivated ALF186
(iALF186) decreased the number of Annexin V positive SH-SY5Y
cells (rotenone-treated 2562% vs. ALF186 10 mmol/L+rotenone
1762%, ALF186 50 mmol/L +rotenone 1562%, ALF 100 mmol/
L+rotenone 1461%, all p,0.001) indicating that CO was likely
mediating the neuroprotection (Fig. 2A–2B). To further corrob-
orate the Annexin findings we measured cleavage of caspase-3 as
a marker of apoptosis. Rotenone caused the degradation of pro-
caspase-3 and formation of caspase-3 cleavage products (Fig. 2B),
which was abrogated in the presence of ALF186. Importantly, the
inactive compound without CO (iALF186) had no effect on
caspase-3 cleavage.
Since rotenone inhibits the mitochondrial electron transfer
chain at complex I, we next analyzed the influence of ALF186 on
rotenone-induced mitochondrial depolarization as an indicator of
apoptosis. Rotenone induced an 87% decrease in mitochondrial
membrane potential over naı ¨ve controls (p,0.05), which was
comparable to depolarization after treatment with cyanide (864%
mitochondrial membrane potential, (Fig. 2C,p ,0.05). ALF186
significantly attenuated mitochondrial depolarization caused by
rotenone (1764% in rotenone+vehicle vs. 5563% in ALF186+ro-
tenone treated, (Fig. 2C,p ,0.05). iALF186 did not prevent
mitochondrial depolarization (iALF+rotenone 1565%).
ALF186 Acts Independently of iNOS and nNOS
To analyze the involvement of heme-containing enzymes as CO
targets in mediating neuroprotection, we next investigated
whether ALF186 influenced activity and expression of the NOS
enzymes. ALF186 induced expression of both the inducible and
neuronal (n) isoforms of NOS (Fig. 3A). ALF186 slightly increased
nitric oxide production and this increase was abolished in the
presence of the NOS-Inhibitor L-NAME (Fig. 3B,p ,0.05).
However, inhibition of NOS with L-NAME did not influence
ALF186 mediated protection against rotenone (Fig. 3C, rotenone
1765% of mitochondrial membrane potential vs. ALF186
50 mmol/L+rotenone 5563% and vs. L-NAME+ALF186+rote-
none 60617%, both p,0.05).
ALF186 Requires Reactive Oxygen Species Originating
from NADPH Oxidase in SH-SY5Y Cells for Protection
CO has been shown to transiently increase ROS in
macrophages by targeting the mitochondria. The effect of CO
on ROS generation in neurons has not been tested. Given the
ability of CO to protect cells against rotenone, we turned to
NADPH oxidase as an alternative hemoprotein target given that
it also generates ROS formation and regulates cell signaling. To
determine whether ALF186 influences intracellular ROS pro-
duction we incubated SH-SY5Y cells with the oxidant dye CM-
H2DCFDA and analyzed ROS production by flow-cytometry.
Incubation with ALF186 alone resulted in a significant increase
in intracellular ROS production comparable to the known
NADPH oxidase inducer PMA (Fig. 4A). Increases in ROS
production by ALF186 or PMA were moderate compared to
the strong induction of ROS by rotenone (Fig. 4A). Inhibition
of NADPH oxidase with diphenylene iodonium (DPI) resulted
in abolishment of ALF186 mediated protection (Fig. 4B).
Interestingly, incubation with DPI alone resulted in a significant
loss in mitochondrial membrane potential (6968% vs. un-
treated, p,0.05) suggesting either that baseline activity of
NADPH oxidase in generating ROS is required for survival or
that DPI has other toxic effects on mitochondria.
ALF186 Induces the Activity and Expression of sGC
To further analyze the influence of ALF186 on heme-contain-
ing potential carbon monoxide targets, we next looked at soluble
guanylate-cyclase (sGC), which is known to be a key target in
vascular smooth muscle [15]. ALF186, but not iALF186
significantly increased the amount of cellular cGMP, the reaction
product of sGC from 2363 nmol/L in control cells to
3365 nmol/L in the presence of 100 mmol/L ALF 186
(Fig. 5A, p,0.05). Increases in the amount of cellular cGMP
by ALF186 were effectively blocked by the sGC-Inhibitor ODQ
(Fig. 5B,p ,0.05). The increase in cGMP likely reflects the ability
of CO to influence sGC activity, however RT-PCR and Western
blot analysis showed that the expression of the sGC b1 subunit was
also induced by ALF186 and not by iALF186 (Fig. 5C).
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Target PKG1 Abrogates ALF186 Mediated Protection
We next asked whether the effects of ALF186 required sGC
activity. Inhibition of sGC activation with the selective inhibitor
ODQ prior to ALF186 incubation and rotenone-treatment led to
mitochondrial depolarization comparable to treatment with
rotenone alone and effectively reversed the protection afforded
by ALF186 (Fig. 6A;1 7 65% rotenone vs. 5563% ALF186+ro-
tenone vs. 2061% ODQ+ALF186+rotenone, p,0.05). Induction
of sGC with YC-1 stabilized mitochondrial membrane potential
(rotenone 1765% of the mitochondrial membrane potential vs.
YC-1+rotenone 3366%, p,0.05), even though this effect was less
pronounced than with ALF186. We next mimicked sGC
activation by incubating cells with the cell-permeable cGMP-
analogue 8-Br-cGMP. Indeed, 8-Br-cGMP afforded significant
protection, which was not as pronounced as that observed with
Figure 2. Effect of ALF186 on rotenone-induced apoptosis. A: Representative experiment after FITC Annexin V and propidiumiodide staining
and flow-cytometric analysis. 1610
4 cells in each experiment were analyzed. B: ALF186-mediated effect on apoptosis analyzed by Annexin V staining
(top, n=6; mean6SD; *=p,0.001 rotenone vs. ALF186 10, 50 and 100 mmol/L+rotenone) and caspase-3 cleavage (bottom, representative Western
blot of caspase-3 cleavage products). C: Flow-cytometric analysis of mitochondrial membrane potential change relative to untreated cells (DYm,
n=6; mean6SD; *=p,0.05 rotenone vs. ALF186+ rotenone and ALF186+ rotenone vs. iALF186+ rotenone).
doi:10.1371/journal.pone.0060672.g002
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PLOS ONE | www.plosone.org 5 April 2013 | Volume 8 | Issue 4 | e60672Figure 3. The role of the heme-containing ‘‘primary’’ CO-target NOS in ALF186 mediated effects. A: Representative western blot of
nNOS and iNOS protein expression after ALF186 treatment. B: Quantification of nitric oxide production by colorimetric measurement of total nitrite
after ALF186 incubation 6NOS-Inhibition by L-NAME (n=6; fold change vs. untreated cells; mean6SD; *=p,0.05 ALF186 vs. L-NAME +ALF186). C:
Flow-cytometric analysis of mitochondrial membrane potential change relative to untreated cells after inhibition of NOS (DYm, n=6; mean6SD;
*=p,0.05 rotenone vs. ALF186+rotenone).
doi:10.1371/journal.pone.0060672.g003
Figure 4. Influence of ALF186 on ROS production and role of NADPH oxidase in ALF186 mediated effects. A: Flow-cytometric analysis
of ROS production after CM-H2DCFDA staining (n=6; mean6SD; *=p,0.05 all vs. untreated; rotenone vs. ALF186 and vs. PMA). B: Flow-cytometric
analysis of mitochondrial membrane potential change relative to untreated cells after NADPH oxidase inhibition (DYm, n=6; mean6SD; *=p,0.05
DPI vs. untreated; rotenone vs. ALF186+rotenone and ALF186+rotenone vs. DPI+ALF186+rotenone).
doi:10.1371/journal.pone.0060672.g004
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PLOS ONE | www.plosone.org 6 April 2013 | Volume 8 | Issue 4 | e60672ALF186 treatment (Fig. 6B). Several downstream targets are
modulated by cGMP, including PKG1. We now asked whether
the cGMP-mediated protective effects were dependent on PKG1
activity. PKG1-inhibition with KT5823 abolished ALF186
mediated protection (Fig. 6C).
ALF186 Protects Retinal Ganglion Cells against Ischemia
Reperfusion Injury in vivo through sGC
In a last set of experiments we translated our in vitro results into
an in vivo model of neuronal cell damage. Retinal ganglion cells
(RGC) are known to be exceptionally susceptible to cell death via
apoptosis when subjected to IRI. We therefore used a well-
described in vivo model of retinal IRI [3] to investigate potential
neuroprotective effects of ALF186 in vivo.
Density-quantification of fluorogold-labeled RGC showed that
retinal tissue from animals receiving intravenous ALF186 treat-
ment before injury had significantly higher ganglion cell densities
compared to animals treated with vehicle alone (Fig. 7A–7B; IRI
12556327 RGC/mm
2 vs. ALF186 10 mg/kg+IRI 2036683,
p,0.05). RGC densities in corresponding control eyes showed no
significant difference from each other (Fig. 7A–7B). In vivo co-
treatment of animals with the sGC-inhibitor NS-2028 abolished
the protective effects mediated by ALF186 (Fig. 7A–7B; ALF186
10 mg/kg+IRI 2036683 RGC/mm
2 vs. NS-2028 7 mg/
kg+ALF186 10 mg/kg+IRI 12636170, p,0.05).
Figure 5. Effect of ALF186 on cellular cGMP levels and expression of sGC. A: ELISA analysis of cellular cGMP concentration after ALF186
treatment (n=6; median625
th/75
th percentile; *=p,0.05 untreated vs. ALF186 10, 50, 100 mmol/L). B: Analysis of cellular cGMP concentration after
ALF186 treatment 6 sGC-Inhibition by ODQ (n=6; median625
th/75
th percentile; *=p,0.05 untreated vs. ALF186 and ALF186 vs. ODQ +ALF186). C:
Effect of ALF186 on sGC b1 subunit mRNA (top; RT-PCR analysis, n=6; median625
th/75
th percentile; *=p,0.05 untreated vs. ALF186 50 mmol/L and
rotenone vs. ALF186 50, 100 mmol/L+rotenone) and protein (bottom, representative Western Blot of sGC b1 protein) expression.
doi:10.1371/journal.pone.0060672.g005
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expression of pro-apoptotic (Caspase-3, Bax) and anti-apoptotic
(Bcl-2) genes using RT-PCR. Expression of Caspase-3 and Bax
was significantly suppressed by ALF186 treatment, whereas sGC-
inhibition abolished this anti-apoptotic effect (Fig. 8A–8B, Bax:
ALF186 10 mg/kg+IRI 1.160.3 fold induction vs. NS-2028
7 mg/kg+ALF186 10 mg/kg+IRI 1.860.4, p,0.05). Expression
of Bcl-2 was not altered, by any treatment (Fig. 8C). In contrast to
in vitro gene expression analyses of the sGC subunits a1 and b1
expression (Fig. 8B), in vivo was not altered by ALF186 (Fig. 8D–
E).
Discussion
The main findings can be summarized as follows: (1) Pre-
treatment with CORM ALF186 attenuates rotenone-induced
apoptosis in SY5Y neuroblastoma cells. (2) ALF186 precondition-
ing influences several heme-containing cellular ‘‘primary’’ targets:
(a) NO-Synthase, (b) NADPH-oxidase-derived ROS and (c) sGC.
(3) ALF186 protects RGC from IRI through inhibition of
apoptosis in vivo that likely involves a similar pathway since sGC
inhibition abolishes the protective effects. We therefore hypoth-
esized that CO arising from ALF186 mediated a series of
interrelated cascades involving a cGMP/NOS/ROS pathway
since inhibition of these pathways at least in vitro abolishes the
protective effects. Protection against apoptosis required cGMP and
ROS generation, but not NOS. We acknowledge that the link
between these signaling molecules requires further study, but we
can conclude that preconditioning with CORM ALF186 protects
neuronal cells in vitro and in vivo from apoptosis and IRI and that
these effects were abrogated when we used the inactive, CO-free
ALF186.
Figure 6. The role of sGC in ALF186 mediated effects. A: Flow-cytometric analysis of mitochondrial membrane potential change relative to
untreated cells after inhibition or induction of sGC (DYm, n=6; mean6SD; *=p,0.05 rotenone vs. ALF186+ rotenone, ALF186+rotenone vs.
ODQ+ALF186+rotenone and rotenone vs. YC-1+rotenone). B: Flow-cytometric analysis after Annexin V staining and incubation with the cGMP-analog
8-Br-cGMP (n=6; mean6SD; *=p,0.05 rotenone vs. ALF186+rotenone and rotenone vs. 8-Br-cGMP+rotenone). C: Flow-cytometric analysis after
Annexin V staining and incubation with the PKG-inhibitor KT5823 (n=6; mean6SD; *=p,0.05 rotenone vs. ALF186+rotenone and ALF186+rotenone
vs. KT5823+ALF186+rotenone).
doi:10.1371/journal.pone.0060672.g006
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profound effects in inhibiting systemic inflammation and apoptosis
in numerous in vitro and in vivo models when given either as a pre-
or postconditioning agent resulting in organoprotective actions
[10,21–28]. CO can also exert protective effects on neuronal cells
in vitro [2,29] and in vivo in small and large animal models
[3,30,31]. The potential human application of CO gas is
challenging to implement not only for technical reasons, which
have been addressed [10], but also for intrinsic flaws including lack
of tissue specificity and at present time, hospital-only administra-
tion [32]. For these reasons, it is crucial to find alternative routes
for the application of CO. CORMs have emerged as an excellent
alternative for delivering CO and have the potential for tissue
specificity. ALF186 does not carry such attributes, yet does clearly
Figure 7. Effect of ALF186 treatment on IRI in retinal ganglion cells in vivo.A :Representative images from flat mounts with fluorogold-
labeled retinal ganglion cells 7 days after IRI, ALF186 treatment and sGC inhibition with NS-2028. Scale bar 100 mm. B: Quantification of retinal
ganglion cell density [cells/mm
2] 7 days after IRI, ALF186 treatment and sGC inhibition in vivo (n=6 per group; mean6SD; *=p,0.05 IRI vs.
ALF186+IRI and ALF186+IRI vs. NS-2028+ALF186+IRI).
doi:10.1371/journal.pone.0060672.g007
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a family of CORMs that are orally active leading to similar
elevations in COHb as when given intraperitoneally or in-
travenously (data not shown) similar to other CORMs
[4,13,17,33–39]. Therefore CORMs represent a safe alternative
for potential clinical application of CO [32]. Unlike CO gas,
which has very simple pharmacokinetics, the CORMs carry more
complicated pharmacologic challenges that need to be assessed.
To date studies on the effects of CORM-3 on neuronal cells and
neuroinflammation have provided inconsistent results [4,5]. With
Figure 8. Effect of ALF186 on retinal caspase-3, Bax, Bcl-2 and sGC-subunit gene expression analyzed by RT-PCR. Retinal expression of
caspase-3 (A; n=6; mean6SD.; *=p,0.05 IRI vs. ALF186+IRI and ALF186+IRI vs. NS-2028+ALF186+IRI), Bax (B; n=6; mean6SD; *=p,0.05 IRI vs.
ALF186+IRI and ALF186+IRI vs. NS-2028+ALF186+IRI), Bcl-2 (C; n=6; mean6SD), sGC a1 subunit (D; n=6; mean6SD) and sGC b1 subunit (E;n=6 ;
mean6SD) mRNA expression in ischemic retinal tissue in relation to the corresponding non-ischemic retinae analyzed by RT-PCR.
doi:10.1371/journal.pone.0060672.g008
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such as ALF186, CO is released upon contact with oxygen. It has
little sensitivity to light and thus features predictable and favorable
CO releasing kinetics with a half life of approximately 15 minutes
in aqueous solvents and media in vitro [6] and fast, bolus-like CO
releasing kinetics in vivo [6], the latter of which is likely due to the
interaction with hemoglobin.
The in vitro model of rotenone-induced apoptosis in SY5Y
neuroblastoma cells is a well-established model of caspase-
dependent neuronal apoptosis [40,41]. It has been extensively
used to study potential neuroprotective effects of endogenous
mediators like prostaglandins [42] or chondroitin sulfate [43] and
drugs like valproic acid [44], hydrogen sulfide [45], tranexamic
acid [46], histamine receptor antagonists [47] or deferoxamine
[48]. Consistent with these previous studies, we found increased
Annexin V positivity, caspase-3 cleavage and mitochondrial
depolarization after rotenone-treatment. Pre-treatment with
ALF186 attenuated apoptosis, which was evidenced by decreased
Annexin V positivity, inhibition in caspase-3 cleavage and
stabilization of mitochondrial membrane potential all of which
were not observed in control experiments with the CO-free
inactive ALF186 (iALF186).
Since CO avidly binds to heme groups of cellular structures
such as NOS, NADPH oxidase or sGC, it is tempting to assume
that the effects of CO are mediated through alteration of such
‘‘primary’’ CO targets. For example, CORM-2 and CORM-3
exhibit anti-inflammatory effects through reduced NO2/nitrite-
production and iNOS expression [11,35,49]. In contrast to these
results, we found that while ALF186 mediated an increase in
iNOS and nNOS protein expression in SY5Y cells, it was not
involved in protection.
CORM-2 exhibited anti-proliferative effects in smooth muscle
cells by blocking NADPH oxidase and the cellular redox system
[12]. In contrast, NADPH oxidase derived ROS can promote cell
survival through increased endogenous CO production in
endothelial cells [50]. Others have found that CO gas mediates
increased mitochondrial-dependent ROS production in macro-
phages [51,52]. In neuronal SY5Y cells, we also observed an
ALF186-mediated increase in ROS production, which we de-
termined to be most likely arising from NADPH oxidase activity as
protection was inhibited by DPI, a selective NADPH oxidase
inhibitor. Perhaps different modes of CO delivery (gas vs. CORM)
can influence the ROS-generating systems of the cell or perhaps
speaks to differences in cell types, neurons vs. macrophages.
Vasorelaxing properties of CORM-3, CORM-A1 and ALF186
have been associated with the induction of the hemoprotein sGC
and a moderate, but significant increase in cGMP production,
activation of PKG1 and downstream activation of calcium-
sensitive potassium channels [9,13,15,53]. Moreover, CO in-
creases retinal and choroidal blood flow in human eyes [54].
However, it is not known whether CORM mediated sGC
induction also modulates neuroprotection. sGC is a heterodimer,
consisting of an a (1 or 2) and heme-containing b (1 or 2) subunit.
Heterodimerization of the enzyme’s a 1 and b 1 subunits is
essentially necessary for the enzyme’s full activity [55,56]. There is
growing evidence that activation of the sGC-cGMP pathway may
also exert cytoprotective and anti-apoptotic effects in neuronal
cells [16]. However, no study has investigated possible CORM-
mediated protective effects in neuronal cells through this pathway.
Protective effects by activation of sGC-cGMP signal transduction
also seem to be mediated through PKG1 activation [16], but little
is known about the downstream targets of PKG1 that mediate
these effects.
The findings of the in vivo study are in accordance with our
previous findings in the same experimental model of retinal injury,
where administration of inhaled CO gas before ischemia was anti-
inflammatory, anti-apoptotic and exerted cytoprotection of RGC
[3]. The degree of neuroprotection was comparable between both
the application of CO gas and ALF186. We delineate here that
ALF186 mediates its neuroprotective effects in vivo through a sGC-
dependent pathway just as the in vitro experiments have demon-
strated. The neuronal cell type and injury model kinetics that we
used in vitro and in vivo differed from one another. However, since
RGC undergo apoptosis after IRI [57,58] similarly to SH-SY5Y
cells do in response to rotenone, both models can be used to assess
apoptosis-related neuronal cell death and CO-mediated neuro-
protection.
Taken together, this study demonstrates that preconditioning
with the novel CORM ALF186 protects neuronal SY5Y and
retinal ganglion cells against ischemic insult in part via a sGC
dependent pathway. CO released from CORMs may therefore be
a treatment option for acute ischemic insults to the retina and the
brain by protecting neurons.
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